07:00 , Jun 25, 2009 |  BC Innovations  |  Cover Story

Low-Rhes approach to Huntington's

A central mystery of Huntington's disease has been why the mutant form of the huntingtin protein responsible for the condition is found throughout the body but only causes pathology in the brain's corpus striatum. Researchers...
08:00 , Nov 6, 2008 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Amyotrophic lateral sclerosis (ALS); transverse myelitis Solute carrier family 1 (glial high affinity glutamate transporter), member 2 (SLC1A2; EAAT2) Rodent studies...
07:00 , Oct 2, 2008 |  BC Innovations  |  Targets & Mechanisms

Moving Upstream in Huntington's

Researchers at Harvard Medical School and The Scripps Research Institute each have published new strategies to treat Huntington's disease, a condition for which there is only one approved drug ( see Attacking Huntington's disease )....
07:00 , Aug 21, 2008 |  BC Innovations  |  Targets & Mechanisms

Stem Cells for ALS

Researchers from Harvard University and Columbia University reported in Science that induced pluripotent stem cells generated from an 82-year-old woman with amyotrophic lateral sclerosis (ALS) could be successfully differentiated into motor neurons and glia. 1...
07:00 , Jun 5, 2008 |  BC Innovations  |  Tools & Techniques

Building Huntington's Monkeys

Building Huntington's Monkeys Efforts to develop treatments for Huntington's disease have been hampered by the lack of utility of rodent models, which do not satisfactorily replicate the physiological and behavioral changes seen in disease patients....
07:00 , Mar 20, 2008 |  BC Innovations  |  Cover Story

The 'Smoking Gun' in ALS

A spate of reports buttresses the case for TDP-43 as a key player in amyotrophic lateral sclerosis. But even though the protein is mislocalized in a majority of patients, drug developers are holding off on...
07:00 , Mar 17, 2008 |  BC Week In Review  |  Clinical News

HD-02: Phase III start

In 3Q08, Avicena will begin a double-blind, placebo-controlled Phase III trial of oral HD-02 in 600 patients. Avicena Group Inc. (OTCBB:AVGO), Palo Alto, Calif.   Product: HD-02   Business: Neurology   Molecular target: Undisclosed  ...
08:00 , Dec 10, 2007 |  BC Week In Review  |  Clinical News

AL-08: Phase II data

Data from the first 60 patients in a double-blind Phase II trial showed that the mean reduction in the ALS Functional Score with once-daily AL-08 plus celecoxib was 5.27 vs. 6.47 with once-daily AL-08 plus...
07:00 , Oct 15, 2007 |  BC Week In Review  |  Company News

Avicena board of directors update

Avicena Group Inc. (AVGO), Palo Alto, Calif.   Business: Neurology   Appointed: CEO Belinda Tsao-Nivaggioli as chairman; she replaces Nasser Menhall, who resigned  ...
07:00 , Oct 1, 2007 |  BC Week In Review  |  Company News

Avicena board of directors update

Avicena Group Inc. (AVGO), Palo Alto, Calif.   Business: Neurology   Appointed: M. Flint Beal, professor and chairman of the department of neurology and neuroscience at the Weill Medical College at Cornell University  ...